Reaction

Lymphangiosis Carcinomatosa reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,029 reports · 56 co-occurring drugs

As of the last recalculation, Lymphangiosis Carcinomatosa appears in 1,029 FAERS reports alongside 56 co-occurring drug terms. The strongest observed disproportionality signal is GEFITINIB (PRR 100.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Gefitinib	43	100.5	101.0
Ado-Trastuzumab Emtansine	21	51.4	51.5
Lapatinib	34	45.8	45.9
Fam-Trastuzumab Deruxtecan-Nxki	22	45.1	45.2
Exemestane	42	41.3	41.4
Osimertinib	54	35.9	36.0
Everolimus	74	31.6	31.7
Pemetrexed	32	31.1	31.2
Pemetrexed Disodium	51	28.4	28.5
Everolimus Tablets	22	27.1	27.1
Trastuzumab	81	25.8	25.9
Letrozole	70	24.6	24.6
Fulvestrant	37	23.5	23.5
Letrozole Tablets	53	23.4	23.5
Erlotinib Hydrochloride	12	19.6	19.6
Paclitaxel (Aibumin-Bound)	74	19.5	19.6
Crizotinib	12	19.3	19.3
Capecitabine	77	18.3	18.3
Paclitaxel	82	18.1	18.1
Docetaxel Anhydrous	57	18.1	18.1
Docetaxel	57	18.1	18.1
Carboplatin	102	17.9	17.9
Irinotecan Hydrochloride	11	17.5	17.5
Pembrolizumab	79	16.4	16.4
Nivolumab	73	16.4	16.4
Pertuzumab	21	15.9	15.9
Ribociclib	24	15.7	15.7
Itraconazole	9	15.7	15.7
Abemaciclib	15	15.4	15.4
Fluorouracil Cream, 0.5%	51	14.2	14.2
Dexamethasone Sodium Phosphate	7	14.0	14.0
Fluorouracil	51	14.0	14.0
Bevacizumab	77	13.5	13.5
Valganciclovir Hydrochloride Powder,	8	13.4	13.4
Trifluridine And Tipiracil	7	13.3	13.3
Sorafenib	13	12.8	12.8
Erlotinib	6	12.6	12.6
Gemcitabine Hydrochloride	31	12.2	12.2
Cisplatin	45	12.1	12.1
Durvalumab	12	12.1	12.1
Gemcitabine	23	12.1	12.1
Granisetron Hydrochloride	6	11.7	11.7
Granisetron	6	11.6	11.6
Cetuximab	17	11.1	11.1
Olaparib	11	10.7	10.7
Dabrafenib	11	10.7	10.7
Panitumumab	8	10.4	10.4
Atezolizumab	19	10.1	10.1
Ipilimumab	19	9.1	9.1
Pazopanib Hydrochloride	11	8.3	8.3
Encorafenib	4	8.2	8.2
Oxaliplatin	29	8.1	8.1
Trametinib	9	7.6	7.6
Vemurafenib	4	6.8	6.8
Cabozantinib	15	6.4	6.4
Lenvatinib	9	5.6	5.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.